The Biotech iShares IBB shot up on some beneficial talk out of the Trump administration and, in my opinion, on beneficial Treasury yield dynamics. So it is no coincidence that it is now consolidating as yields have spiked.
With yields nearing resistance and momo hype wearing off, I wonder if the correction will make it all the way to well defined support around 300 or simply flag to the (orange dotted) EMA 20 before turning up again. The upside target remains 350.
Subscribe to NFTRH Premium for your 40-55 page weekly report, interim updates and NFTRH+ chart and trade ideas or the free eLetter for an introduction to our work. Or simply keep up to date with plenty of public content at NFTRH.com and Biiwii.com. Also, you can follow via Twitter @BiiwiiNFTRH, StockTwits, RSS or sign up to receive posts directly by email (right sidebar).